Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.32 | N/A | +8.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.32 | N/A | +8.16% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over market conditions impacting performance. They remain focused on their strategic goals but acknowledged the difficulties ahead.
Management highlighted ongoing challenges in the current market environment.
They emphasized their commitment to long-term strategies despite short-term setbacks.
Madrigal Pharmaceuticals reported a wider-than-expected loss per share, resulting in a 1.86% decline in stock price. The lack of revenue information and no guidance updates contributed to investor uncertainty. Management's defensive tone suggests they are navigating a challenging environment, which may affect future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REVVITY INC
Apr 28, 2025